This presentation describes results from the FARETINA-AMD study which is a retrospective real world study using data from the IRIS registry (USA). Data were analyzed February 2022 - March 2023 to identify faricimab▼ starts among patients diagnosed with DME and with at least 12 months of treatment with faricimab▼. Results show vision and anatomic improvement in treatment-naïve eyes and stable vision and anatomic improvement in previously treated eyes. Fewer injections were observed from 6 months onwards, suggesting treatment interval extension.
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management.
Not a healthcare professional? Browse:
This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. This global website is intended for healthcare professionals outside the UK, US, Canada, and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications, and services that are not approved or valid in your country. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.